In the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial [14], 4401 patients with T2D and CKD were randomized to receive SGLT-2 inhibitor therapy with canagliflozin at a dose of 100 mg/day or placebo. The gene discussed is SLC5A2; the disease is chronic kidney disease.